くすりのしおり

Self-injection
Published: 3/2018

The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment.
Brand name :
Repatha SC injection 140mg pen
 Active ingredient:
Evolocumab(genetical recombination)
 Dosage form:
Colorless to slight yellowish liquid for injection in prefilled syringe (clear to opalescent liquid may contain translucent to white amorphous)
 Print on wrapping:

Effects of this medicine

This medicine promotes cholesterol uptake in liver and reduces blood cholesterol level.
It is usually used to treat familial hypercholesterolemia or hypercholesterolemia.

Before using this medicine, be sure to tell your doctor and pharmacist

  • If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.
    If you have liver disease.
  • If you are pregnant or breastfeeding.
  • If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)

Dosing schedule (How to take this medicine)

  • Your dosing schedule prescribed by your doctor is ((        to be written by a healthcare professional))
  • For heterozygous familial hypercholesterolemia or hypercholesterolemia: In general, for adults, 140mg of evolocumab (genetical recombination) is administrated subcutaneously every 2 weeks or 420mg of evolocumab is administrated subcutaneously every 4 weeks.
    For homozygous familial hypercholesterolemia: In general, for adults, 420mg of evolocumab (genetical recombination) is administrated subcutaneously every 4 weeks. In case of insufficient response, 420mg of evolocumab can be administered subcutaneously every 2 weeks. If evolocumab is administered as adjunctive therapy for patients with LDL apheresis, as starting dose, 420mg of evolocumab can be administered subcutaneously every 2 weeks.
  • It may be administered over a long period of time according to your response to the treatment.
  • The sites for injection are abdomen, thighs and upper arms. You cannot inject this medicine into the outside of upper arm by yourself.
  • Tests are performed regularly, and if insufficient reaction to this medicine is confirmed as a result, use of this medicine may be discontinued.
  • If you miss a dose, contact with your doctor and receive advice.
  • If you accidentally inject more than your prescribed dose, consult with your doctor or pharmacist.
  • Do not stop injecting this medicine unless your doctor instructs you to do so.

Precautions while taking this medicine

  • Strictly follow the instructions on dietary/exercise therapy or cessation of smoking if instructed to do so by your doctor.

Possible adverse reactions to this medicine

The most commonly reported adverse reactions include diabetes mellitus, injection site reaction and muscular pain. If any of these symptoms occur, consult with your doctor or pharmacist.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.
No pertinent entries.
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.

Storage conditions and other information

  • Keep out of the reach of children. Keep the medicine in the outer carton, store away from light, and avoid freezing. Store it in the refrigerator, etc. (at 2 to 8 degrees Celsius).
  • Discard the remainder. Do not store them. Ask the pharmacist and the medical institution how to discard them.

For healthcare professional use only : Day Month Year

For further information, talk to your doctor or pharmacist.